annual CFF:
$12.13M-$341.39M(-96.57%)Summary
- As of today (September 10, 2025), XENE annual cash flow from financing activities is $12.13 million, with the most recent change of -$341.39 million (-96.57%) on December 31, 2024.
- During the last 3 years, XENE annual CFF has fallen by -$435.41 million (-97.29%).
- XENE annual CFF is now -97.29% below its all-time high of $447.54 million, reached on December 31, 2021.
Performance
XENE Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$87.20K-$1.06M(-92.42%)Summary
- As of today (September 10, 2025), XENE quarterly cash flow from financing activities is $87.20 thousand, with the most recent change of -$1.06 million (-92.42%) on June 1, 2025.
- Over the past year, XENE quarterly CFF has increased by +$87.20 thousand (+100.00%).
- XENE quarterly CFF is now -99.97% below its all-time high of $322.06 million, reached on December 31, 2021.
Performance
XENE quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$13.12M+$87.20K(+0.67%)Summary
- As of today (September 10, 2025), XENE TTM cash flow from financing activities is $13.12 million, with the most recent change of +$87.20 thousand (+0.67%) on June 1, 2025.
- Over the past year, XENE TTM CFF has dropped by -$337.20 million (-96.25%).
- XENE TTM CFF is now -97.82% below its all-time high of $601.07 million, reached on June 30, 2022.
Performance
XENE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
XENE Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -96.6% | +100.0% | -96.3% |
| 3 y3 years | -97.3% | -100.0% | -97.8% |
| 5 y5 years | -55.9% | +100.5% | -88.3% |
XENE Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -97.3% | at low | -100.0% | +101.3% | -97.8% | +236.5% |
| 5 y | 5-year | -97.3% | at low | -100.0% | +100.5% | -97.8% | +236.5% |
| alltime | all time | -97.3% | +376.3% | -100.0% | +100.5% | -97.8% | +236.5% |
XENE Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $87.20K(-92.4%) | $13.12M(+0.7%) |
| Mar 2025 | - | $1.15M(-90.3%) | $13.03M(+9.7%) |
| Dec 2024 | $12.13M(-96.6%) | $11.88M(>+9900.0%) | $11.88M(-96.3%) |
| Sep 2024 | - | $0.00(0.0%) | $320.69M(-8.5%) |
| Jun 2024 | - | $0.00(0.0%) | $350.32M(0.0%) |
| Mar 2024 | - | $0.00(-100.0%) | $350.32M(0.0%) |
| Dec 2023 | $353.52M(+27.0%) | $320.69M(+982.2%) | $350.32M(+1414.4%) |
| Sep 2023 | - | $29.63M(>+9900.0%) | $23.13M(-340.6%) |
| Jun 2023 | - | $0.00(0.0%) | -$9.61M(-103.7%) |
| Mar 2023 | - | $0.00(-100.0%) | $259.16M(-2.9%) |
| Dec 2022 | $278.47M(-37.8%) | -$6.50M(+108.8%) | $267.03M(-55.2%) |
| Sep 2022 | - | -$3.11M(-101.2%) | $595.60M(-0.9%) |
| Jun 2022 | - | $268.77M(+3312.5%) | $601.07M(+79.8%) |
| Mar 2022 | - | $7.88M(-97.6%) | $334.26M(-24.9%) |
| Dec 2021 | $447.54M(+421.6%) | $322.06M(>+9900.0%) | $445.10M(+257.7%) |
| Sep 2021 | - | $2.36M(+20.7%) | $124.44M(-0.0%) |
| Jun 2021 | - | $1.96M(-98.4%) | $124.49M(+19.1%) |
| Mar 2021 | - | $118.72M(+8348.7%) | $104.56M(+18.4%) |
| Dec 2020 | $85.80M(+211.8%) | $1.41M(-41.6%) | $88.31M(-22.9%) |
| Sep 2020 | - | $2.41M(-113.4%) | $114.48M(+2.1%) |
| Jun 2020 | - | -$17.97M(-117.5%) | $112.09M(-13.8%) |
| Mar 2020 | - | $102.47M(+271.6%) | $130.07M(+370.2%) |
| Dec 2019 | $27.52M | $27.57M(>+9900.0%) | $27.66M(<-9900.0%) |
| Sep 2019 | - | $18.90K(+75.0%) | -$229.00K(-100.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2019 | - | $10.80K(-81.4%) | $75.81M(-30.7%) |
| Mar 2019 | - | $58.00K(-118.3%) | $109.46M(-0.1%) |
| Dec 2018 | $111.59M(+1478.4%) | -$316.70K(-100.4%) | $109.52M(-6.3%) |
| Sep 2018 | - | $76.05M(+125.9%) | $116.87M(+186.3%) |
| Jun 2018 | - | $33.67M(>+9900.0%) | $40.83M(+469.9%) |
| Mar 2018 | - | $119.00K(-98.3%) | $7.16M(-0.8%) |
| Dec 2017 | $7.07M(-70.5%) | $7.03M(>+9900.0%) | $7.22M(-2173.1%) |
| Sep 2017 | - | $9300.00(+481.3%) | -$348.20K(-101.5%) |
| Jun 2017 | - | $1600.00(-99.1%) | $23.89M(-0.2%) |
| Mar 2017 | - | $174.00K(-132.6%) | $23.92M(+0.5%) |
| Dec 2016 | $23.96M(+8520.1%) | -$533.10K(-102.2%) | $23.79M(-2.3%) |
| Sep 2016 | - | $24.24M(>+9900.0%) | $24.36M(>+9900.0%) |
| Jun 2016 | - | $40.70K(-7.5%) | $137.10K(-25.2%) |
| Mar 2016 | - | $44.00K(+18.3%) | $183.40K(-31.2%) |
| Dec 2015 | $278.00K(-99.3%) | $37.20K(+144.7%) | $266.40K(-99.4%) |
| Sep 2015 | - | $15.20K(-82.5%) | $41.52M(+1.4%) |
| Jun 2015 | - | $87.00K(-31.5%) | $40.93M(+1.0%) |
| Mar 2015 | - | $127.00K(-99.7%) | $40.51M(+1.3%) |
| Dec 2014 | $41.12M(-1036.6%) | $41.29M(-7317.6%) | $39.99M(-3180.9%) |
| Sep 2014 | - | -$572.10K(+71.8%) | -$1.30M(+78.8%) |
| Jun 2014 | - | -$333.00K(-15.3%) | -$726.00K(+84.7%) |
| Mar 2014 | - | -$393.00K | -$393.00K |
| Dec 2013 | -$4.39M(<-9900.0%) | - | - |
| Dec 2012 | $0.00(-100.0%) | - | - |
| Dec 2011 | $2000.00 | - | - |
FAQ
- What is Xenon Pharmaceuticals Inc. annual cash flow from financing activities?
- What is the all time high annual CFF for Xenon Pharmaceuticals Inc.?
- What is Xenon Pharmaceuticals Inc. annual CFF year-on-year change?
- What is Xenon Pharmaceuticals Inc. quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Xenon Pharmaceuticals Inc.?
- What is Xenon Pharmaceuticals Inc. quarterly CFF year-on-year change?
- What is Xenon Pharmaceuticals Inc. TTM cash flow from financing activities?
- What is the all time high TTM CFF for Xenon Pharmaceuticals Inc.?
- What is Xenon Pharmaceuticals Inc. TTM CFF year-on-year change?
What is Xenon Pharmaceuticals Inc. annual cash flow from financing activities?
The current annual CFF of XENE is $12.13M
What is the all time high annual CFF for Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. all-time high annual cash flow from financing activities is $447.54M
What is Xenon Pharmaceuticals Inc. annual CFF year-on-year change?
Over the past year, XENE annual cash flow from financing activities has changed by -$341.39M (-96.57%)
What is Xenon Pharmaceuticals Inc. quarterly cash flow from financing activities?
The current quarterly CFF of XENE is $87.20K
What is the all time high quarterly CFF for Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. all-time high quarterly cash flow from financing activities is $322.06M
What is Xenon Pharmaceuticals Inc. quarterly CFF year-on-year change?
Over the past year, XENE quarterly cash flow from financing activities has changed by +$87.20K (+100.00%)
What is Xenon Pharmaceuticals Inc. TTM cash flow from financing activities?
The current TTM CFF of XENE is $13.12M
What is the all time high TTM CFF for Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. all-time high TTM cash flow from financing activities is $601.07M
What is Xenon Pharmaceuticals Inc. TTM CFF year-on-year change?
Over the past year, XENE TTM cash flow from financing activities has changed by -$337.20M (-96.25%)